Literature DB >> 15077221

Evolution of responding CD4+ and CD8+ T-cell repertoires during the development of graft-versus-host disease directed to minor histocompatibility antigens.

Thea M Friedman1, Stephen C Jones, Debbie Statton, George F Murphy, Robert Korngold.   

Abstract

Graft-versus-host disease (GVHD) can be induced in lethally irradiated mice after allogeneic bone marrow transplantation between major histocompatibility complex-matched strains expressing multiple minor histocompatibility antigen differences. In the B6 --> BALB.B irradiation model, both CD4(+) and CD8(+) donor T cells have the capacity to mediate lethal GVHD. Previously, CDR3-size spectratyping was used to analyze these T-cell responses at a single early time point (day 5) after transplantation and revealed clonal or oligoclonal expansions of the V beta 2, 4, and 6 to 14 families for the CD4(+) response and of the V beta 4, 6, 8 to 11, and 14 families for the B6 CD8(+) response. Appropriate positive selection of these T-cell receptor V beta-skewed CD4(+) and CD8(+) T-cell subsets and their subsequent transfer into lethally irradiated BALB.B recipients resulted in fatal GVHD induction. In contrast, BALB.B mice transplanted with nonskewed V beta CD4(+) T cells survived, with minimal symptoms of GVHD. This study was undertaken to investigate the evolution of the donor/antihost minor histocompatibility antigen T-cell repertoire responses throughout the course of GVHD development. The results indicated that a number of V beta families were consistently involved throughout the course of GVHD, whereas some V beta families exhibited skewed expansions only in either the early or late stages of disease. In addition, sequence analysis of relevant representative skewed CDR3 bands from the CD4(+) V beta 11(+) and the CD8(+) V beta 14(+) families, both of which exhibited strong consistent responses, demonstrated increased use of the J beta 2.5 and J beta 2.4 segments, respectively, thus identifying the T-cell receptor specificities involved.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15077221     DOI: 10.1016/j.bbmt.2003.12.303

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  9 in total

1.  Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells.

Authors:  Tomomi Toubai; Isao Tawara; Yaping Sun; Chen Liu; Evelyn Nieves; Rebecca Evers; Thea Friedman; Robert Korngold; Pavan Reddy
Journal:  Blood       Date:  2011-11-18       Impact factor: 22.113

2.  Inter-strain tissue-infiltrating T cell responses to minor histocompatibility antigens involved in graft-versus-host disease as determined by Vbeta spectratype analysis.

Authors:  Jenny Zilberberg; Danielle McElhaugh; Loise N Gichuru; Robert Korngold; Thea M Friedman
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

Review 3.  Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.

Authors:  Jenny Zilberberg; Rena Feinman; Robert Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-20       Impact factor: 5.742

4.  T-cell receptor V(alpha) usage by effector CD4+Vbeta11+ T cells mediating graft-versus-host disease directed to minor histocompatibility antigens.

Authors:  Christine G DiRienzo; George F Murphy; Thea M Friedman; Robert Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2007-03       Impact factor: 5.742

5.  Treatment with GM-CSF secreting myeloid leukemia cell vaccine prior to autologous-BMT improves the survival of leukemia-challenged mice.

Authors:  Jenny Zilberberg; Thea M Friedman; Glenn Dranoff; Robert Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-12       Impact factor: 5.742

6.  PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.

Authors:  Wolfgang Koestner; Martin Hapke; Jessica Herbst; Christoph Klein; Karl Welte; Joerg Fruehauf; Andrew Flatley; Dario A Vignali; Matthias Hardtke-Wolenski; Elmar Jaeckel; Bruce R Blazar; Martin G Sauer
Journal:  Blood       Date:  2010-11-09       Impact factor: 22.113

7.  T-cell receptor Valpha spectratype analysis of a CD4-mediated T-cell response against minor histocompatibility antigens involved in severe graft-versus-host disease.

Authors:  Christine G DiRienzo; George F Murphy; Stephen C Jones; Robert Korngold; Thea M Friedman
Journal:  Biol Blood Marrow Transplant       Date:  2006-08       Impact factor: 5.742

Review 8.  Target cells in graft-versus-host disease: implications for cancer therapy.

Authors:  George F Murphy
Journal:  Clin Rev Allergy Immunol       Date:  2007-08-14       Impact factor: 8.667

9.  Overlap between in vitro donor antihost and in vivo posttransplantation TCR Vbeta use: a new paradigm for designer allogeneic blood and marrow transplantation.

Authors:  Thea M Friedman; Kira Goldgirsh; Stephanie A Berger; Jenny Zilberberg; Joanne Filicko-O'Hara; Neal Flomenberg; Michele Donato; Scott D Rowley; Robert Korngold
Journal:  Blood       Date:  2008-06-09       Impact factor: 22.113

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.